A clinical trial to study the effect of Rewand chini (a herbal drug) in patients with painful menstruation.

Efficacy of Rewand chini (Rheum emodi) in the management of Primary dysmenorrhoea

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2014/08/004924

Enrollment

Registered

2014-08-25

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Patients suffering from Primary Dysmenorrhoea

Interventions

Intervention1: Rewand chini (Rheum emodi) 2.5 gm for 5 days for three consecutive cycles.: Rheum emodi was powdered and filled in capsules. 3 capsules of drug given two days before the expected date o

Eligibility

Inclusion criteria

Inclusion criteria: Unmarried patients of primary dysmenorrhoea belongs to above age group with regular menstrual cycle were included in the study.

Exclusion criteria

Exclusion criteria: Patients with pelvic pathology, irregular cycles, systemic illness, allergic to NSAIDs, married women and mild dysmenorrhoea were excluded.

Design outcomes

Primary

Measure	Time frame
Change in severity of pain (assessed by visual analogue scale and verbal multidimensional scoring system) and change in duration of pain from baseline to the last follow up.Timepoint: Visual analogue scale 1-10 Verbal multidimensional scoring system 0-3	—

Secondary

Measure	Time frame
secondary outcome measures were overall improvement of dysmenorrhoea and improvement in quality of life (QOL)from baseline to last follow upTimepoint: QOL 0-10	—

Countries

India

Contacts

Public ContactDr Wajeeha Begum

National Institute of Unani Medicine, Kottigepalya, Bangalore

drwajeehanium@gmail.com9972550185

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026